Dr. Tenner studies how to enhance the experience of patients suspected of having pancreatic cancer by leveraging computer technology. His research looks specifically at how this technology can help identify these patients more effectively and expedite their access to necessary medical procedures, such as biopsies, as well as oncology appointments. By finding quicker ways for patients to receive care, his work aims to improve their chances of better health outcomes, particularly for diverse groups who may face barriers to timely treatment.
Key findings
The implementation of a new system reduced the time for patients to receive a biopsy from 12 days to 6 days.
Wait times for oncology appointments decreased from 27 days to 17 days after the new patient finding system was introduced.
These changes demonstrate the potential for technology to create more efficient processes in healthcare, which can benefit patients significantly.
Frequently asked questions
Does Dr. Tenner study pancreatic cancer?
Yes, Dr. Tenner focuses on improving care and access for patients suspected of having pancreatic cancer.
What treatments has Dr. Tenner researched?
His research mainly examines the use of technology to streamline processes, such as biopsies and oncology appointments, rather than specific treatments.
Is Dr. Tenner's work relevant to patients facing delays in cancer care?
Yes, his work directly addresses issues related to access and speed of care for pancreatic cancer patients.
Publications in plain English
Computationally assisted patient finding for navigation to optimize pancreatic cancer care access.
2026
The oncologist
King DA, John KM, Tenner J, Nadella S, Zavadsky T +13 more
Plain English This study examined how using computer technology to identify patients with pancreatic cancer can speed up their access to care. Researchers found that, after implementing this new system, the time it took for patients to get a biopsy dropped from 12 to 6 days, and the wait for oncology appointments decreased from 27 to 17 days, although these changes weren't statistically significant. This matters because faster access to treatment can potentially lead to better outcomes for patients, especially among diverse demographic groups.
Who this helps: Patients suspected of having pancreatic cancer.